[1] A. Cuadrado and A. Nebreda, “Mechanisms and functions of
p38 MAPK signalling,” Biochemical Journal, vol. 429, no. 3,
pp. 403–417, 2010.
[2] Z. Wang, P. C. Harkins, R. J. Ulevitch, J. Han, M. H. Cobb,
and E. J. Goldsmith, “The structure of mitogen-activated
protein kinase p38 at 2.1-°a resolution,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 94, no. 6, pp. 2327–2332, 1997.
[3] R. Ben-Levy, S. Hooper, R. Wilson, H. F. Paterson, and C.
J. Marshall, “Nuclear export of the stress-activated protein
kinase p38 mediated by its substrate MAPKAP kinase-2,”
Current Biology, vol. 8, no. 19, pp. 1049–1057, 1998.
[4] T. Tomida, M. Takekawa, P. O’Grady, and H. Saito, “Stimulus-
specific distinctions in spatial and temporal dynamics
of stress-activated protein kinase kinase kinases revealed by a
fluorescence resonance energy transfer biosensor,” Molecular
and Cellular Biology, vol. 29, no. 22, pp. 6117–6127, 2009.
[5] A. Cuenda and S. Rousseau, “P38 MAP-kinases pathway regulation,
function and role in human diseases,” Biochimica et
Biophysica Acta, vol. 1773, no. 8, pp. 1358–1375, 2007.
[6] A. Risco and A. Cuenda, “New insights into the p38 γ and
p38 δ MAPK pathways,” Journal of Signal Transduction, vol.
2012, Article ID 520289, 8 pages, 2012.
[7] L. Munoz and A. J. Ammit, “Targeting p38 MAPK pathway
for the treatment of Alzheimer’s disease,” Neuropharmacology,
vol. 58, no. 3, pp. 561–568, 2010.
[8] J. D. English and J. D. Sweatt, “A requirement for the mitogen-
activated protein kinase cascade in hippocampal long
term potentiation,” The Journal of Biological Chemistry, vol.
272, no. 31, pp. 19103–19106, 1997.
[9] G. M. Thomas and R. L. Huganir, “MAPK cascade signalling
and synaptic plasticity,” Nature Reviews Neuroscience, vol. 5,
no. 3, pp. 173–183, 2004.
[10] V. A. Beardmore, H. J. Hinton, C. Eftychi et al., “Generation
and characterization of p38β (MAPK11) gene-targeted
mice,” Molecular and Cellular Biology, vol. 25, no. 23, pp.
10454–10464, 2005.
[11] S. H. Lee, J. Park, Y. Che, P. L. Han, and J. K. Lee, “Constitutive
activity and differential localization of p38α and
p38β MAPKs in adult mouse brain,” Journal of Neuroscience
Research, vol. 60, no. 5, pp. 623–631, 2000.
[12] J. Bain, L. Plater, M. Elliott et al., “The selectivity of protein
kinase inhibitors: a further update,” Biochemical Journal, vol.
408, no. 3, pp. 297–315, 2007.
[13] J. Da Silva, B. Pierrat, J. L.Mary, andW. Lesslauer, “Blockade
of p38 mitogen-activated protein kinase pathway inhibits inducible
nitric-oxide synthase expression in mouse astrocytes,”
The Journal of Biological Chemistry, vol. 272, no. 45,
pp. 28373–28380, 1997.
[14] J. I. Kakimura, Y. Kitamura, K. Takata et al., “Microglial activation
and amyloid-β clearance induced by exogenous heatshock
proteins,” FASEB Journal, vol. 16, no. 6, pp. 601–603,
2002.
[15] C. Richter-Landsberg, A.Wyttenbach, and A. P. Arrigo, “The
role of heat shock proteins during neurodegeneration in
Alzheimer’s, Parkinson’s and Huntington’s disease,” in Heat
Shock Proteins inNeural Cells, pp. 81–99, Springer, New York,
NY, USA, 2009.
[16] G. L. Collingridge, J. T. R. Isaac, and Y. T. Wang, “Receptor
trafficking and synaptic plasticity,” Nature Reviews Neuroscience,
vol. 5, no. 12, pp. 952–962, 2004.
[17] J. D. Shepherd and R. L. Huganir, “The cell biology of synaptic
plasticity: AMPA receptor trafficking,” Annual Review
of Cell and Developmental Biology, vol. 23, pp. 613–643, 2007.
[18] G. L. Collingridge, S. Peineau, J. G. Howland, and Y. T.Wang,
“Long-term depression in the CNS,” Nature Reviews Neuroscience,
vol. 11, no. 7, pp. 459–473, 2010.
[19] C. M. Gladding, S. M. Fitzjohn, and E. Moln´ar, “Metabotropic
glutamate receptor-mediated long-term depression:
molecular mechanisms,” Pharmacological Reviews, vol. 61,
no. 4, pp. 395–412, 2009.
[20] P. R. Moult, S. A. L. Corrˆea, G. L. Collingridge, S. M.
Fitzjohn, and Z. I. Bashir, “Co-activation of p38 mitogenactivated
protein kinase and protein tyrosine phosphatase
underlies metabotropic glutamate receptor-dependent longterm
depression,” Journal of Physiology, vol. 586, no. 10, pp.
2499–2510, 2008.
[21] J. Arthur, “MSK activation and physiological roles,” Frontiers
in Bioscience, vol. 13, pp. 5866–5879, 2008.
[22] B. G. Frenguelli and S. A. L. Corrˆea, “Regulation and role of
MSK in the mammalian brain,” in MSKs, J. S. C. Arthur, Ed.,
Landes Bioscience, Austin, Tex, USA, 2012.
[23] C. C. Huang, J. L. You, M. Y. Wu, and K. S. Hsu, “Rap1-
induced p38 mitogen-activated protein kinase activation facilitates AMPA receptor trafficking via the GDI·Rab5
complex: potential role in (S)-3,5-dihydroxyphenylglycineinduced
long term depression,” The Journal of Biological
Chemistry, vol. 279, no. 13, pp. 12286–12292, 2004.
[24] J. G. Hanley, “AMPA receptor trafficking pathways and
links to dendritic spine morphogenesis,” Cell Adhesion &
Migration, vol. 2, no. 4, pp. 276–282, 2008.
[25] J. Han, J. D. Lee, L. Bibbs, and R. J. Ulevitch, “A MAP kinase
targeted by endotoxin and hyperosmolarity in mammalian
cells,” Science, vol. 265, no. 5173, pp. 808–811, 1994.
[26] J. Rouse, P. Cohen, S. Trigon et al., “A novel kinase cascade
triggered by stress and heat shock that stimulates MAPKAP
kinase-2 and phosphorylation of the small heat shock proteins,”
Cell, vol. 78, no. 6, pp. 1027–1037, 1994.
[27] N.W. Freshney, L. Rawlinson, F. Guesdon et al., “Interleukin-
1 activates a novel protein kinase cascade that results in the
phosphorylation of Hsp27,” Cell, vol. 78, no. 6, pp. 1039–
1049, 1994.
[28] Y. Shi and M. Gaestel, “In the cellular garden of forking
paths: how p38 MAPKs signal for downstream assistance,”
Biological Chemistry, vol. 383, no. 10, pp. 1519–1536, 2002.
[29] M. Gaestel, “MAPKAP kinases—MKs—two’s company,
three’s a crowd,” Nature Reviews Molecular Cell Biology, vol.
7, no. 2, pp. 120–130, 2006.
[30] A. White, C. A. Pargellis, J. M. Studts, B. G. Werneburg, and
B. T. Farmer, “Molecular basis of MAPK-activated protein
kinase 2: p38 assembly,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 104, no. 15, pp.
6353–6358, 2007.
[31] L. J. Vician, G. Xu,W. Liu, J. D. Feldman, H. B.Machado, and
H. R. Herschman, “MAPKAP kinase-2 is a primary response
gene induced by depolarization in PC12 cells and in brain,”
Journal of Neuroscience Research, vol. 78, no. 3, pp. 315–328,
2004.
[32] D. Stokoe, K. Engel, D. G. Campbell, P. Cohen, and M.
Gaestel, “Identification of MAPKAP kinase 2 as a major
enzyme responsible for the phosphorylation of the small
mammalian heat shock proteins,” FEBS Letters, vol. 313, no.
3, pp. 307–313, 1992.
[33] L. New and J. Han, “The p38 MAP kinase pathway and its
biological function,” Trends in Cardiovascular Medicine, vol.
8, no. 5, pp. 220–228, 1998.
[34] S. Singh, D. W. Powell, M. J. Rane et al., “Identification of
the p16-Arc subunit of the Arp 2/3 complex as a substrate of
MAPK-activated protein kinase 2 by proteomic analysis,” The
Journal of Biological Chemistry, vol. 278, no. 38, pp. 36410–
36417, 2003.
[35] C. E. Eyers, H. McNeill, A. Knebel et al., “The phosphorylation
of capz-interacting protein (capzip) by stress-activated
protein kinases triggers its dissociation from capz,” Biochemical
Journal, vol. 389, part 1, pp. 127–135, 2005.
[36] C. K. Huang, L. Zhan, Y. Ai, and J. Jongstra, “Lsp1 is the major
substrate for mitogen-activated protein kinase-activated
protein kinase 2 in human neutrophils,” The Journal of
Biological Chemistry, vol. 272, no. 1, pp. 17–19, 1997.
[37] N. Ronkina,M.Menon, J. Schwermann et al., “Stress induced
gene expression: a direct role for MAPKAP kinases in
transcriptional activation of immediate early genes,” Nucleic
Acids Research, vol. 39, no. 7, pp. 2503–2518, 2011.
[38] S. A. Pintchovski, C. L. Peebles, H. J. Kim, E. Verdin, and S.
Finkbeiner, “The serum response factor and a putative novel
transcription factor regulate expression of the immediateearly
gene Arc/Arg3.1 in neurons,” Journal of Neuroscience,
vol. 29, no. 5, pp. 1525–1537, 2009.
[39] C. R. Bramham, M. N. Alme, M. Bittins et al., “The Arc of
synaptic memory,” Experimental Brain Research, vol. 200, no.
2, pp. 125–140, 2010.
[40] C. L. Peebles, J. Yoo,M. T. Thwin, J. J. Palop, J. L. Noebels, and
S. Finkbeiner, “Arc regulates spine morphology and maintains
network stability in vivo,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 107,
no. 42, pp. 18173–18178, 2010.
[41] S. Chowdhury, J. D. Shepherd, H. Okuno et al., “Arc/Arg3. 1
interacts with the endocytic machinery to regulate AMPA receptor
trafficking,” Neuron, vol. 52, no. 3, pp. 445–459, 2006.
[42] J. Wu, R. S. Petralia, H. Kurushima et al., “Arc/Arg3. 1 regulates
an endosomal pathway essential for activity-dependent
β-amyloid generation,” Cell, vol. 147, no. 3, pp. 615–628,
2011.
[43] C. Ballatore, M. Y. L. Virginia, and J. Q. Trojanowski, “Taumediated
neurodegeneration in Alzheimer’s disease and related
disorders,” Nature Reviews Neuroscience, vol. 8, no. 9,
pp. 663–672, 2007.
[44] D. P. Hanger, B. H. Anderton, and W. Noble, “Tau phosphorylation:
the therapeutic challenge for neurodegenerative
disease,” Trends inMolecularMedicine, vol. 15, no. 3, pp. 112–
119, 2009.
[45] B. R. Hoover, M. N. Reed, J. Su et al., “Tau mislocalization
to dendritic spines mediates synaptic dysfunction independently
of neurodegeneration,” Neuron, vol. 68, no. 6, pp.
1067–1081, 2010.
[46] L. Martin, X. Latypova, and F. Terro, “Post-translational
modifications of tau protein: implications for Alzheimer’s
disease,”Neurochemistry International, vol. 58, no. 4, pp. 458–
471, 2011.
[47] L. Bu´ee, T. Bussi`ere, V. Bu´ee-Scherrer, A. Delacourte, and
P. R. Hof, “Tau protein isoforms, phosphorylation and role
in neurodegenerative disorders,” Brain Research Reviews, vol.
33, no. 1, pp. 95–130, 2000.
[48] L. I. Binder, A. Frankfurter, and L. I. Rebhun, “The distribution
of tau in the mammalian central nervous system,”
Journal of Cell Biology, vol. 101, no. 4, pp. 1371–1378, 1985.
[49] C. Dotti, G. Banker, and L. Binder, “The expression and
distribution of the microtubule-associated proteins tau and
microtubule-associated protein 2 in hippocampal neurons in
the rat in situ and in cell culture,” Neuroscience, vol. 23, no. 1,
pp. 121–130, 1987.
[50] J. W. Mandell and G. A. Banker, “A spatial gradient of tau
protein phosphorylation in nascent axons,” Journal of Neuroscience,
vol. 16, no. 18, pp. 5727–5740, 1996.
[51] J. Avila, J. J. Lucas, M. P´erez, and F. Hern´andez, “Role of tau
protein in both physiological and pathological conditions,”
Physiological Reviews, vol. 84, no. 2, pp. 361–384, 2004.
[52] S. C. Papasozomenos and L. I. Binder, “Phosphorylation determines
two distinct species of tau in the central nervous system,”
CellMotility and the Cytoskeleton, vol. 8, no. 3, pp. 210–
226, 1987.
[53] C. A. Dickey, A. Kamal, K. Lundgren et al., “The high-affinity
HSP90-CHIP complex recognizes and selectively degrades
phosphorylated tau client proteins,” The Journal of Clinical
Investigation, vol. 117, no. 3, pp. 648–658, 2007.
[54] A. Sengupta, J. Kabat, M. Novak, Q. Wu, I. Grundke-Iqbal,
and K. Iqbal, “Phosphorylation of tau at both Thr 231 and
Ser 262 is required for maximal inhibition of its binding to
microtubules,” Archives of Biochemistry and Biophysics, vol.
357, no. 2, pp. 299–309, 1998.
[55] W. J. Streit, R. E. Mrak, and W. S. T. Griffin, “Microglia and
neuroinflammation: a pathological perspective,” Journal of
Neuroinflammation, vol. 1, article 14, 2004.
[56] C. Chao, S. Hu, and P. Peterson, “Glia, cytokines, and neurotoxicity,”
Critical Reviews in Neurobiology, vol. 9, no. 2-3, pp.
189–205, 1995.
[57] S. D. Skaper, “The brain as a target for inflammatory processes
and neuroprotective strategies,” Annals of the New York
Academy of Sciences, vol. 1122, no. 1, pp. 23–34, 2007.
[58] S. J. Harper and P. Lograsso, “Signalling for survival and
death in neurones: the role of stress-activated kinases, JNK
and p38,” Cellular Signalling, vol. 13, no. 5, pp. 299–310,
2001.
[59] T.Obata, G. E. Brown, andM. B. Yaffe, “Map kinase pathways
activated by stress: the p38 MAPK pathway,” Critical Care
Medicine, vol. 28, no. 4, pp. 67–77, 2000.
[60] A. Kotlyarov, A. Neininger, C. Schubert et al., “MAPKAP
kinase 2 is essential for LPS-induced TNF-α biosynthesis,”
Nature Cell Biology, vol. 1, no. 2, pp. 94–97, 1999.
[61] N. Fyhrquist, S. Matikainen, and A. Lauerma, “MK2 signaling:
lessons on tissue specificity in modulation of inflammation,”
Journal of Investigative Dermatology, vol. 130, no. 2, pp.
342–344, 2010.
[62] A. Neininger, D. Kontoyiannis, A. Kotlyarov et al., “MK2
targets AU-rich elements and regulates biosynthesis of tumor
necrosis factor and interleukin-6 independently at different
post-transcriptional levels,” The Journal of Biological Chemistry,
vol. 277, no. 5, pp. 3065–3068, 2002.
[63] A. A. Culbert, S. D. Skaper, D. R. Howlett et al., “MAPKactivated
protein kinase 2 deficiency in microglia inhibits
pro-inflammatory mediator release and resultant neurotoxicity:
relevance to neuroinflammation in a transgenic mouse
model of Alzheimer disease,” The Journal of Biological Chemistry,
vol. 281, no. 33, pp. 23658–23667, 2006.
[64] R. Brookmeyer, E. Johnson, K. Ziegler-Graham, and H. M.
Arrighi, “Forecasting the global burden of Alzheimer’s disease,”
Alzheimer’s and Dementia, vol. 3, no. 3, pp. 186–191,
2007.
[65] S. T. DeKosky and S.W. Scheff, “Synapse loss in frontal cortex
biopsies in Alzheimer’s disease: correlation with cognitive
severity,” Annals of Neurology, vol. 27, no. 5, pp. 457–464,
1990.
[66] M. Knobloch and I. M. Mansuy, “Dendritic spine loss and
synaptic alterations in Alzheimer’s disease,”Molecular Neurobiology,
vol. 37, no. 1, pp. 73–82, 2008.
[67] I. Ferrer, F. Cruz-Sanchez, N. Guionnet, and T. Tunon, “A
study of senile plaques with a combined method in brains
of patients suffering from Alzheimer’s disease,” Archivos de
Neurobiologia, vol. 53, no. 6, pp. 222–226, 1990.
[68] P. Penzes and J. E. VanLeeuwen, “Impaired regulation of
synaptic actin cytoskeleton in Alzheimer’s disease,” Brain
Research Reviews, vol. 67, no. 1-2, pp. 184–192, 2011.
[69] P. N. Lacor, M. C. Buniel, L. Chang et al., “Synaptic targeting
by Alzheimer’s-related amyloid β oligomers,” Journal of
Neuroscience, vol. 24, no. 45, pp. 10191–10200, 2004.
[70] P. N. Lacor, M. C. Buniel, P. W. Furlow et al., “Aβ oligomerinduced
aberrations in synapse composition, shape, and
density provide a molecular basis for loss of connectivity in
Alzheimer’s disease,” Journal of Neuroscience, vol. 27, no. 4,
pp. 796–807, 2007.
[71] K. Hensley, R. A. Floyd, N. Y. Zheng et al., “P38 kinase is
activated in the Alzheimer’s disease brain,” Journal of Neurochemistry,
vol. 72, no. 5, pp. 2053–2058, 1999.
[72] T. A. Fulga, I. Elson-Schwab, V. Khurana et al., “Abnormal
bundling and accumulation of F-actin mediates tau-induced
neuronal degeneration in vivo,” Nature Cell Biology, vol. 9,
no. 2, pp. 139–148, 2007.
[73] D. M.Moraga, P. Nunez, J. Garrido, and R. B.Maccioni, “A τ
fragment containing a repetitive sequence induces bundling
of actin filaments,” Journal of Neurochemistry, vol. 61, no. 3,
pp. 979–986, 1993.
[74] P. K. Krishnamurthy and G. V.W. Johnson, “Mutant (r406w)
human tau is hyperphosphorylated and does not efficiently
bind microtubules in a neuronal cortical cell model,” The
Journal of Biological Chemistry, vol. 279, no. 9, pp. 7893–
7900, 2004.
[75] G. A. Farias, J. P. Munoz, J. Garrido, and R. B. Maccioni,
“Tubulin, actin, and tau protein interactions and the study
of their macromolecular assemblies,” Journal of Cellular
Biochemistry, vol. 85, no. 2, pp. 315–324, 2002.
[76] J. Z. Yu and M. M. Rasenick, “Tau associates with actin in
differentiating PC12 cells,” FASEB Journal, vol. 20, no. 9, pp.
1452–1461, 2006.
[77] H. He, X. Wang, R. Pan, D.Wang, M. Liu, and R. He, “The
proline-rich domain of tau plays a role in interactions with
actin,” BMC Cell Biology, vol. 10, no. 1, article 81, 2009.
[78] P. Hotulainen and C. C. Hoogenraad, “Actin in dendritic
spines: connecting dynamics to function,” Journal of Cell
Biology, vol. 189, no. 4, pp. 619–629, 2010.
[79] D. L. Rocca, S. Martin, E. L. Jenkins, and J. G. Hanley,
“Inhibition of Arp2/3-mediated actin polymerization by
PICK1 regulates neuronal morphology and AMPA receptor
endocytosis,” Nature Cell Biology, vol. 10, no. 3, pp. 259–271,
2008.
[80] Y. Nakamura, C. L. Wood, A. P. Patton et al., “PICK1
inhibition of the Arp2/3 complex controls dendritic spine
size and synaptic plasticity,” EMBO Journal, vol. 30, no. 4, pp.
719–730, 2011.
[81] H. Pyo, I. Jou, S. Jung, S. Hong, and E. Joe, “Mitogen-activated
protein kinases activated by lipopolysaccharide and β-
amyloid in cultured rat microglia,” Neuroreport, vol. 9, no. 5,
pp. 871–874, 1998.
[82] L. Munoz, H. Ranaivo, S. Roy et al., “A novel p38α MAPK
inhibitor suppresses brain proinflammatory cytokine upregulation
and attenuates synaptic dysfunction and behavioral
deficits in an Alzheimer’s diseasemouse model,” Journal
of Neuroinflammation, vol. 4, no. 1, article 21, 2007.
[83] S. H. Kim, C. J. Smith, and L. J. Van Eldik, “Importance of
MAPK pathways for microglial pro-inflammatory cytokine
IL-1β production,” Neurobiology of Aging, vol. 25, no. 4, pp.
431–439, 2004.
[84] A. M. Bodles and S.W. Barger, “Secreted β-amyloid precursor
protein activates microglia via JNK and p38-MAPK,” Neurobiology
of Aging, vol. 26, no. 1, pp. 9–16, 2005.
[85] D. T. Weldon, S. D. Rogers, J. R. Ghilardi et al., “Fibrillar β-
amyloid induces microglial phagocytosis, expression of inducible
nitric oxide synthase, and loss of a select population of
neurons in the rat CNS in vivo,” Journal of Neuroscience, vol.
18, no. 6, pp. 2161–2173, 1998.
[86] K. Shigematsu, P.McGeer, D.Walker, T. Ishii, and E.McGeer,
“Reactive microglia/macrophages phagocytose amyloid precursor
protein produced by neurons following neural damage,”
Journal of Neuroscience Research, vol. 31, no. 3, pp. 443–
453, 1992.
[87] M. G. Giovannini, C. Scali, C. Prosperi et al., “β-amyloidinduced
inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway,”
Neurobiology of Disease, vol. 11, no. 2, pp. 257–274, 2002.
[88] Y. Li, L. Liu, S.W. Barger, andW. S. T. Griffin, “Interleukin-1
mediates pathological effects of microglia on tau phosphorylation
and on synaptophysin synthesis in cortical neurons
through a p38-MAPK pathway,” Journal of Neuroscience, vol.
23, no. 5, pp. 1605–1611, 2003.
[89] I. Ferrer, “Stress kinases involved in tau phosphorylation in
Alzheimer’s disease, tauopathies and APP transgenic mice,”
Neurotoxicity Research, vol. 6, no. 6, pp. 469–475, 2004.
[90] M. J. Savage, Y. G. Lin, J. R. Ciallella, D. G. Flood, and R. W.
Scott, “Activation of c-jun N-terminal kinase and p38 in an
Alzheimer’s disease model is associated with amyloid deposition,”
Journal of Neuroscience, vol. 22, no. 9, pp. 3376–3385,
2002.
[91] X. Zhu, C. A. Rottkamp, A. Hartzler et al., “Activation of
MKK6, an upstream activator of p38, in Alzheimer’s disease,”
Journal of Neurochemistry, vol. 79, no. 2, pp. 311–318, 2001.
[92] Y. Hashimoto, T. Niikura, T. Chiba et al., “The cytoplasmic
domain of Alzheimer’s amyloid-β protein precursor causes
sustained apoptosis signal-regulating kinase 1/c-Jun NH 2-
terminal kinase-mediated neurotoxic signal via dimerization,”
Journal of Pharmacology and Experimental Therapeutics,
vol. 306, no. 3, pp. 889–902, 2003.
[93] A. L. Peel, N. Sorscher, J. Y. Kim, V. Galvan, S. Chen, and
D. E. Bredesen, “Tau phosphorylation in Alzheimer’s disease:
potential involvement of an APP-MAP kinase complex,”
Neuromolecular Medicine, vol. 5, no. 3, pp. 205–218, 2004.
[94] G. T. Bramblett, M. Goedert, R. Jakes, S. E.Merrick, J. Q. Trojanowski,
and V. M. Y. Lee, “Abnormal tau phosphorylation
at Ser396 in Alzheimer’s disease recapitulates development
and contributes to reduced microtubule binding,” Neuron,
vol. 10, no. 6, pp. 1089–1099, 1993.
[95] A.W.Hartzler, X. Zhu, S. L. Siedlak et al., “The p38 pathway
is activated in pick disease and progressive supranuclear
palsy: a mechanistic link between mitogenic pathways,
oxidative stress, and tau,” Neurobiology of Aging, vol. 23, no.
5, pp. 855–859, 2002.
[96] Parkinson’s UK, Number of people with Parkinson’s in the
uk set to rise, 2012, http://www.parkinsons.org.uk/about us/
news/news items/all news/new parkinsons prevalence.aspx.
[97] W. Poewe, “Non-motor symptoms in Parkinson’s disease,”
European Journal of Neurology, vol. 15, no. 1, pp. 14–20, 2008.
[98] S. Lesage and A. Brice, “Parkinson’s disease: from monogenic
forms to genetic susceptibility factors,” Human Molecular
Genetics, vol. 18, no. 1, pp. R48–R59, 2009.
[99] M. R. Cookson, “α-synuclein and neuronal cell death,” Molecular
Neurodegeneration, vol. 4, no. 1, article 9, 2009.
[100] A. Klegeris, S. Pelech, B. I. Giasson et al., “α-synuclein activates
stress signaling protein kinases in THP-1 cells and microglia,”
Neurobiology of Aging, vol. 29, no. 5, pp. 739–752,
2008.
[101] T. Thomas, M. Timmer, K. Cesnulevicius, E. Hitti, A.
Kotlyarov, and M. Gaestel, “MAPKAP kinase 2-deficiency
prevents neurons from cell death by reducing neuroinflammation—
relevance in amouse model of Parkinson’s disease,”
Journal of Neurochemistry, vol. 105, no. 5, pp. 2039–2052,
2008.